Company Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.
The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial.
The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.
Immatics N.V. is headquartered in Tübingen, Germany.
| Country | Germany |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 535 |
| CEO | Harpreet Singh |
Contact Details
Address: Paul-Ehrlich-Strasse 15 Tübingen, 72076 Germany | |
| Phone | 49 7071 5397 0 |
| Website | immatics.com |
Stock Details
| Ticker Symbol | IMTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001809196 |
| CUSIP Number | N44445109 |
| ISIN Number | NL0015285941 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Harpreet Singh Ph.D. | Chief Executive Officer, MD, Member of Management Board and Executive Director |
| Dr. Toni Weinschenk Ph.D. | Co-Founder and Chief Innovation Officer |
| Arnd Christ MBA | Chief Financial Officer |
| Steffen Walter Ph.D. | Chief Operations Officer |
| Edward A. Sturchio | General Counsel and Secretary |
| Dr. Carsten Reinhardt M.D., Ph.D. | Chief Development Officer |
| Cedrik M. Britten M.D. | Chief Medical Officer |
| Jordan Silverstein | Head of Strategy |
| Dr. Hans-Georg Rammensee Ph.D. | Co-Founder and Member of the Scientific Advisory Board |
| Ephraim Hofsäß M.Sc. | Vice President of SEC Reporting and Accounting |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 6-K | Report of foreign issuer |
| Nov 18, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 15, 2024 | 6-K | Report of foreign issuer |
| Oct 11, 2024 | 424B2 | Prospectus |
| Oct 10, 2024 | 424B2 | Prospectus |